The first published journals in the medical field reflected the needs of a closed group of doctors delineated by their particular field of practice or specialty. However, the world, the need for more and better information, and the dissemination of information have changed radically over time. It is this need to service the continuously growing and developing area of Innovations in Digital Health, Diagnostics and Biomarkers (IDDB) that drives us to present this new journal to the global readership.


There are a number of distinct reasons that justify the creation of this journal. The information explosion in healthcare is well known. The increase in both journals and published articles exploring innovation is increasing dramatically. However, as most other journals focus on one discipline, there are no other available multidisciplinary journals on innovation such as the current one. Journals dealing with topics in health services, medical decision making, research, and innovation are usually focused on specific methodologies; whereas others interested in broader topics, such as healthcare technology assessment, are focused on the link to implementing or researching such technologies in depth. IDDB will publish articles with a specific combination of attributes that are not replicated elsewhere and together result in the unique position of the journal.

Secondly, new methods of enquiry are emerging in thinking about innovations in the wider healthcare field, and that is inevitably also reflected in the approaches of understanding and implementing those findings. It is such findings that need to be translated into new, interpretable, and actionable knowledge about the efficient and appropriate use of innovation. Thirdly, the number and composition of the IDDB potential readership, such as scholars, clinicians, managers, data analysts, policy makers, and private companies, who are interested and active in this sphere has also grown substantially over the last years. New methods of studying the implications and cost of innovations are now extant; and there is widespread interest in knowing how these innovations will impact our healthcare and diagnostics.


IDDB has attracted editors and reviewers who have the experience and are best placed to recognize quality scholarship regardless of its substantive focus and/or its choice of methods. Additionally, IDDB aims to be a truly international journal, as great innovations easily cross national boundaries to impact many. We will publish innovative research done in all regions of the world so that none seem marginalised within the field. Other journals make this claim too; however, please examine the set of editors assembled by the journal. They represent already a great variation of countries, cultures, and languages. It is our responsibility not only to review manuscripts, but also to solicit quality scholarship within their geographic region and field of expertise.

Thus, IDDB will stand for a combination of insightful presentation of research and rigorous peer review. It will offer a unique opportunity to combine many elements that might attract the attention of a wide variety of audiences as needed by this subject matter. We intend to welcome contributions from many different academic and clinical disciplines while upholding the standards of good science and good writing. Furthermore, understanding what doesn't work as well as what does work will underline those clear insights and underscore the utility of both evidence and findings. The research published here will use state-of-the-art methods. Understanding this diversity is critical.


IDDB seeks contributions from authors around the world, covering all types of human disease, in the form of original research, reviews, case reports, and more. The Journal aims to serve as a platform for timely dissemination of the latest innovations in digital health, diagnostics, and biomarkers. IDDB welcomes original research articles, including observational studies and randomized clinical trials and surveys; reviews; brief communications; case reports; letters to the editors; editorials and commentary, as described online and in detail.

A Word About Biomarkers

The subject areas of biomarkers will not be restricted only to biological biomarkers, but will include biomarkers in the wider sense, always related to healthcare, such as radiological biomarkers for example. Digital health trials and trial designs are aimed at offering a new perspective in the nexus of health trials that will see innovations in digital health implemented into real world practice. Similarly, data analytics, machine-learning and artificial intelligence in diagnostics will offer a wide-spectrum of perspectives in digital health that can support the implementation of innovations in the field. Mobile health and digital health in resource limited settings complete the set of topics at IDDB, proof of the global outlook of the journal.

It is a great honour to lead and work with a group of outstanding personalities from North America, Australia, China, and Europe and from a broad range of biomedical disciplines serving as members of the editorial board, committed to the mission and scope of the journal. We hope that you will read our published articles, submit your research, and contribute to peer-review and discussion. We commit to being an excellent source of scientific information, having our email door of communication always open, and look forward to working with the entire community relating to Innovations in Digital Health, Diagnostics, and Biomarkers.

Competing Interests

Sources of Support: None; Conflict of Interest: None.

Author notes

Where authors are identified as personnel of the International Agency for Research on Cancer / WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / WHO.